Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders

被引：0
|
作者：
Trapè, G [1 ]
Fianchi, L [1 ]
Lai, M [1 ]
Laurenti, L [1 ]
Piscitelli, R [1 ]
Leone, G [1 ]
Pagano, L [1 ]
机构：
[1] Univ Cattolica Sacro Cuore, Ist Ematol, Dept Hematol, I-00168 Rome, Italy
来源：
HAEMATOLOGICA | 2003年 / 88卷 / 02期
关键词：
lymphoproliferative disorders; rituximab; autaimmune hemolytic anemia;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We administered rituximab monoclonal antibody to five patients suffering from a lymphoproliferative CD20-positive disease associated, at diagnosis or after starting treatment, with autoimmune hemolytic anemia (AIHA). After treatment with rituximab we observed an improvement of AIHA in all cases, and, in one case, improvement of the autoimmune thrombocytopenia associated with the AIHA. There were no relevant side effects.
引用
收藏
页码：223 / 225
页数：3
相关论文
共 50 条
  • [21] Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three cases
    Zompi, S
    Tulliez, M
    Conti, F
    Leblond, V
    Gaulard, P
    Blanche, P
    Durand, F
    Ghandi, D
    Dreyfus, F
    Louvel, A
    Calmus, Y
    Bouscary, D
    JOURNAL OF HEPATOLOGY, 2000, 32 (03) : 521 - 527
  • [22] Refractory autoimmune cytopenias, either associated with lymphoproliferative diseases or idiopathic in adult patients, treated with anti-CD20 monoclonal antibody (Rituximab).
    Garay, G
    Riveros, D
    Milone, J
    Fernandez, J
    Duarte, P
    Cacchione, R
    Dupont, J
    BLOOD, 2004, 104 (11) : 238B - 238B
  • [23] Successful treatment of refractory low grade duodenal lymphoma with rituximab, an anti-cd20 monoclonal antibody
    Ahmed, S
    Singh, A
    Krauss, J
    Wentz, T
    Gunaratnam, NT
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (04): : 408 - 410
  • [24] Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders
    Castillo, Jorge
    Milani, Cannon
    Mendez-Allwood, Daniel
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (04) : 491 - 500
  • [25] Chimeric monoclonal anti-CD20 antibody (rituximab) - an effective treatment for a patient with relapsing hairy cell leukaemia
    Hagberg, H
    MEDICAL ONCOLOGY, 1999, 16 (03) : 221 - 222
  • [26] Chimeric monoclonal anti-CD20 antibody (rituximab)—an effective treatment for a patient with relapsing hairy cell leukaemia
    H Hagberg
    Medical Oncology, 1999, 16 : 221 - 222
  • [27] Anti-CD20 monoclonal antibody (rituximab) administration in patients with refractory immunologic thrombocytopenic purpura.
    Rosenthal, E
    Karsenti, JM
    Pesce, A
    Cassuto, JP
    BLOOD, 2001, 98 (11) : 525A - 525A
  • [28] Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab)
    Cooper, HL
    Healy, E
    Theaker, JM
    Friedmann, PS
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2003, 28 (04) : 366 - 368
  • [29] Anti-cd20 monoclonal antibody treatment (rituximab) in acute lymphoblastic leukemia
    Jándula, BM
    Nomdedeu, J
    Marín, P
    Muñoz, L
    Vivancos, P
    BONE MARROW TRANSPLANTATION, 2001, 27 : S92 - S92
  • [30] Treatment of Cutaneous Lymphoid Hyperplasia with the Monoclonal Anti-CD20 Antibody Rituximab
    Martin, Stephanie J.
    Duvic, Madeleine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (03): : 286 - 288
12345